ORGANISATIONAL MODEL OF DENTAL SUPPORT FOR PATIENTS WITH ORAL MUCOSAL CANCER: STAGE-BASED ALGORITHMS, DIGITAL SALIVARY PH MONITORING AND QUALITY-OF-LIFE OUTCOMES
DOI:
https://doi.org/10.5281/zenodo.23942731Keywords:
oral mucosal cancer, dental support, organisation of care, salivary pH, remote monitoring, quality of lifeAbstract
In Uzbekistan, patients with oral mucosal cancer are referred late, and dental care during and after oncological treatment lacks a defined pathway. We substantiated an organisational model that includes stage-based dental algorithms, digital remote monitoring of salivary pH by the patients themselves and a dental support centre at the oncology dispensary, and evaluated it in 79 patients with extended dental support compared with 162 patients under standard follow-up, with quality of life assessed in a series of 320 patients. At 12 months, salivary pH remained at 6.0 or above in 100% of the main group versus 21.0% of the comparison group (p<0.001), ECOG 0 status was more frequent with dental support (45% vs 31%; p=0.02), and the OHIP-14 score for everyday life improved from 15.92 to 12.22. The model keeps the oral environment stable and improves quality of life, which justifies establishing dental support centres at oncology dispensaries.References
1. Bray, F., Laversanne, M., Sung, H., Ferlay, J., Siegel, R. L., Soerjomataram, I., & Jemal, A. (2024). Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 74(3), 229–263. https://doi.org/10.3322/caac.21834
2. Khazratov, A. I., Rizaev, Zh. A., Alieva, D. A., & Ganiev, A. A. (2024). Epidemiological assessment of oral cancer incidence in the world and the situation in the Republic of Uzbekistan. Journal of Oral Medicine and Craniofacial Research. 2024;5(3). (In Russian).
3. Epstein, J. B., Thariat, J., Bensadoun, R. J., Barasch, A., Murphy, B. A., Kolnick, L., et al. (2012). Oral complications of cancer and cancer therapy: from cancer treatment to survivorship. CA Cancer J Clin, 62(6), 400–422. https://doi.org/10.3322/caac.21157
4. Sroussi, H. Y., Epstein, J. B., Bensadoun, R. J., Saunders, D. P., Lalla, R. V., Migliorati, C. A., et al. (2017). Common oral complications of head and neck cancer radiation therapy: mucositis, infections, saliva change, fibrosis, sensory dysfunctions, dental caries, periodontal disease, and osteoradionecrosis. Cancer Med, 6(12), 2918–2931. https://doi.org/10.1002/cam4.1221
5. Brook, I. (2020). Late side effects of radiation treatment for head and neck cancer. Radiat Oncol J, 38(2), 84–92. https://doi.org/10.3857/roj.2020.00213
6. Peterson, D. E., Koyfman, S. A., Yarom, N., Lynggaard, C. D., Ismaila, N., Forner, L. E., et al. (2024). Prevention and management of osteoradionecrosis in patients with head and neck cancer treated with radiation therapy: ISOO-MASCC-ASCO guideline. J Clin Oncol, 42(16), 1975–1996. https://doi.org/10.1200/JCO.23.02750
7. Kawashita, Y., Soutome, S., Umeda, M., & Saito, T. (2020). Oral management strategies for radiotherapy of head and neck cancer. Jpn Dent Sci Rev, 56(1), 62–67. https://doi.org/10.1016/j.jdsr.2020.02.001
8. Ubaydullaev, Kh., Gafforov, S., & Gafur-Akhunov, M. (2019). Comprehensive rehabilitation of patients with malignant tumours and defects of the maxillofacial region. Stomatologiya. 2019;(3):76. (In Russian).
9. Jensen, S. B., Pedersen, A. M., Vissink, A., Andersen, E., Brown, C. G., Davies, A. N., et al. (2010). A systematic review of salivary gland hypofunction and xerostomia induced by cancer therapies: prevalence, severity and impact on quality of life. Support Care Cancer, 18(8), 1039–1060. https://doi.org/10.1007/s00520-010-0827-8
10. Hosseini, M. S., Sanaie, S., & Mahmoodpoor, A. (2024). Jabbari Beyrami S, Jabbari Beyrami H, Fattahi S, et al. Cancer treatment-related xerostomia: basics, therapeutics, and future perspectives. Eur J Med Res. 2024;29(1):571. basics.
11. Basch, E., Deal, A. M., Kris, M. G., Scher, H. I., Hudis, C. A., Sabbatini, P., et al. (2016). Symptom monitoring with patient-reported outcomes during routine cancer treatment: a randomized controlled trial. J Clin Oncol, 34(6), 557–565. https://doi.org/10.1200/JCO.2015.63.0830
12. Slade, G. D. (1997). Derivation and validation of a short-form oral health impact profile. Community Dent Oral Epidemiol, 25(4), 284–290. https://doi.org/10.1111/j.1600-0528.1997.tb00941.x
13. Bossola, M. (2015). Nutritional interventions in head and neck cancer patients undergoing chemoradiotherapy: a narrative review. Nutrients, 7(1), 265–276. https://doi.org/10.3390/nu7010265
14. Karnofsky, D. A., & Burchenal, J. H. (1949). The clinical evaluation of chemotherapeutic agents in cancer. In: MacLeod CM, editor. Evaluation of Chemotherapeutic Agents. New York: Columbia University Press; 1949. p. 191–205.
15. Oken, M. M., Creech, R. H., Tormey, D. C., Horton, J., Davis, T. E., McFadden, E. T., et al. (1982). Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol, 5(6), 649–655.

